Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2016 / Articles / Sep / Accelerating the development of generic pharmaceuticals
Discovery & Development Biosimilars Business Practice Clinical Trials Drug Delivery Ingredients Formulation Small Molecules Bioprocessing - Single Use Systems Dosage Forms Technology and Equipment Analytical Science Trends & Forecasts Development & Clinical Drug Delivery Formulation Small Molecules Bioprocessing Biopharma Facilities & Equipment Technology & Manufacturing

Accelerating the development of generic pharmaceuticals

09/06/2016 1 min read

Share

Developing an Analytical Toolkit Suitable for De-formulating Complex Reference Products In its report ‘Critical Path Opportunities for Generic Drugs’, the FDA emphasizes the need for advances in the field of analytical sciences in order to accelerate the development of generic products. Here, Paul Kippax highlights techniques that are especially helpful in the deformulation of complex reference products, focusing on triple detection Size Exclusion Chromatography (SEC) and Morphologically-Directed Raman Spectroscopy (MDRS).

Case Study 1: Decoding the Molecular Weight and Grade of Polymers Commonly Used to Modify Release of API in an Oral Solid Dose Formulation Case Study 2: Focusing on Characterization of the AP >> Download the full article for FREE  

Malvern Instruments provides the materials and biophysical characterization technology and expertise that enable scientists and engineers to understand and control the properties of dispersed systems. These systems range from proteins and polymers in solution, particle and nanoparticle suspensions and emulsions, through to sprays and aerosols, industrial bulk powders and high concentration slurries. Used at all stages of research, development and manufacturing, Malvern’s materials characterization instruments provide critical information that helps accelerate research and product development, enhance and maintain product quality and optimize process efficiency. Our products reflect Malvern’s drive to exploit the latest technological innovations and our commitment to maximizing the potential of established techniques. They are used by both industry and academia, in sectors ranging from pharmaceuticals and biopharmaceuticals to bulk chemicals, cement, plastics and polymers, energy and the environment. Malvern systems are used to measure particle size, particle shape, zeta potential, protein charge, molecular weight, mass, size and conformation, rheological properties and for chemical identification, advancing the understanding of dispersed systems across many different industries and applications. Headquartered in Malvern, UK, Malvern Instruments has subsidiary organizations in all major European markets, North America, Mexico, China, Japan and Korea, a joint venture in India, a global distributor network and applications laboratories around the world. www.malvern.com severine.michel@malvern.com

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

The Monoclonal Milestone
Biosimilars
The Monoclonal Milestone

December 1, 2014

0 min read

The launch of the world’s first biosimilar monoclonal antibody was a big step forward from a regulatory and scientific standpoint. Will there be enough room at the table?

Safety First - Sizing Up Biologics Side Effects
Standards & Regulation Biosimilars
Safety First - Sizing Up Biologics Side Effects

December 2, 2014

0 min read

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.

Singular Head of Generics
Biosimilars
Singular Head of Generics

November 6, 2014

0 min read

Sitting Down With… Nick Haggar, Head of Western Europe, Middle East & Africa, Sandoz, and President of the European Generic Medicines Association (EGA).

Celebrating the Potential of Biosimilars
Supply Chain Biosimilars Bioprocessing - Upstream & Downstream
Celebrating the Potential of Biosimilars

February 5, 2025

3 min read

A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in national and international healthcare systems.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.